Abstracts tagged "T-Regulatory Cells"

Abstract Number: 118 • 2019 ACR/ARP Annual Meeting
Polymorphonuclear Neutrophils and Regulatory T Lymphocytes (Treg) Cooperate to Sustain Treg Activity but This Interaction Is Altered in Rheumatoid Arthritis Patients
Maxime Batignes ¹, François Santinon ¹, Marie-Christophe Boissier ², Patrice Decker ¹ and Natacha Bessis¹, ¹Inserm UMR 1125, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ²Assistance Publique-Hôpitaux de Paris (AP-HP), Rheumatology Department, Avicenne Hospital, Bobigny, France
Background/Purpose: Regulatory T cells (Treg) are necessary for immune homeostasis but are functionally deficient in inflammatory/autoimmune diseases such as rheumatoid arthritis (RA). On the other…
Abstract Number: 1063 • 2019 ACR/ARP Annual Meeting
Effects of Abatacept on T Regulatory Cells in Early Diffuse Systemic Sclerosis
David Fox¹, Michael Whitfield ², Veronica Berrocal ³, Steven K. Lundy ⁴, Phillip Campbell ⁵, Stephanie Rasmussen ⁵, Ray Ohara ⁶, Alexander Stinson ⁶, Evan Wiewiora ⁷, Cathie Spino ⁷, Erica Bush ⁸, Daniel Furst ⁹, Shiv Pillai ¹⁰ and Dinesh Khanna ¹¹, ¹Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence,University of Michigan, Ann Arbor, MI, ²Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hannover, NH, ³Department of Biostatistics, School of Publich Health, University of Michigan, Ann Arbor, MI, ⁴TBD, Seattle, WA, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁶Washington University, St. Louis, MO, ⁷Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, ⁸Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁹University of California at Los Angeles, Los Angeles, CA, ¹⁰Ragon Institude of MGH, MIT and Harvard, Charlestown, MA, ¹¹Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence, University of Michigan, Ann Arbor
Background/Purpose: Background: In a randomized controlled trial of abatacept in early diffuse systemic sclerosis (Khanna D, et al ACR 2018), we observed early clinical flares…
Abstract Number: 1293 • 2019 ACR/ARP Annual Meeting
Multiple Subpopulations of Lymphocytes Were Absolutely Decreased in Dermatomyositis/polymyositis Patients and Restored by Low-dose IL-2
Jia Wang ¹, He-hua Sun ¹, Sheng-xiao Zhang², Jia-qian Zhang ¹, Jiang Bai ³, Jing Luo ³, Cai-hong Wang ⁴, Chong Gao ⁵ and Xiao-feng Li ¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ²The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ³Shanxi Medical University, Taiyuan, China (People's Republic), ⁴The Second Hospital of Shanxi Medical University, Tai Yuan, China (People's Republic), ⁵Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare chronicinflammatory disorders with significant associated morbidityand mortality despite treatment, characterized by subacute onset of proximal muscle weakness,…
Abstract Number: 2879 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Low-dose IL-2 in Rebuilting Immunity Re-equilibrium of Psoriatic Arthritis Patients
Jia Wang ¹, Yu-fei Hao ², Sheng-xiao Zhang², Quan-run Li ³, Jing-yuan Yang ³, Jia-qian Zhang ¹, Guang-ying Liu ¹, Chong Gao ⁴ and Xiao-feng Li ¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ²The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ³Shanxi Medical University, Taiyuan, China (People's Republic), ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Psoriatic arthritis (PsA) is a T lymphocytes-mediated inflammatory condition. Although regulatory T cells (Tregs) isolated from blood and psoriatic skin have been showed a…
Abstract Number: 87 • 2019 ACR/ARP Annual Meeting
KINE-101, a Novel Synthetic Peptide with Potent Regulatory T Cells Activation to Treat Rheumatoid Arthritis
Myun Soo Kim ¹, Sora Lee ¹, Jung Hyun Roh ¹, Jung A Kwon ¹, Sunyoung Park¹ and Daeho Cho ², ¹KINE SCIENCES Co. Ltd., Seoul, Republic of Korea, ²Institute of convergence science/Korea university, Seoul, Republic of Korea
Background/Purpose: Medical and patient unmet needs still existed in rheumatoid arthritis (RA) global market due to the side effects treated for long duration and sometimes…
Abstract Number: 95 • 2019 ACR/ARP Annual Meeting
IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE
Hiroshi Kato¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: IL-21 activates mechanistic target of rapamycin (mTOR) complexes 1 and 2 which in turn block regulatory T (Treg)-cell differentiation and function in patients with…
Abstract Number: 112 • 2019 ACR/ARP Annual Meeting
Impact of Interleukin-9 on the Immune Suppressive Functions of Regulatory T Cells in Rheumatoid Arthritis
Sushmita Chakraborty ¹, Ranjan Gupta ², Rinkee Kumari ¹ and Dipendra Kumar Mitra¹, ¹All India Institute of Medical Sciences, Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: An important component of the immune tolerance is regulatory T cells (Tregs), which prevents autoimmunity and restrains inflammatory reactions. In Rheumatoid Arthritis (RA), there…
Abstract Number: 47 • 2018 ACR/ARHP Annual Meeting
Analysis of the Role of RORγt+Foxp3+ T Regulatory 17 (Tr17) Cells in Murine Autoimmune Arthritis Model
Kotona Furuyama¹, Yuya Kondo¹, Masaru Shimizu², Iizuka Akira¹, Masahiro Yokosawa¹, Seiji Segawa¹, Hiroto Tsuboi¹, Isao Matsumoto¹ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Internal Medicine, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: RORγt+Foxp3+ regulatory T (Treg) cells, designated as Tr17 is one of the new subset of Treg cells, having the potential to regulate the development…
Abstract Number: 52 • 2018 ACR/ARHP Annual Meeting
Interferon-Alpha Protects Against Pain and Joint Damages in Experimental Arthritis and Is Associated with Expansion of Highly Suppressive Regulatory T Lymphocytes in Protected Mice and in Tocilizumab-Treated Rheumatoid Arthritis Patients
Matthieu Ribon¹, Roxane Hervé², Delphine Lemeiter², Katarzyna Matyja¹, François Santinon¹, Darragh Duffy³, Ken Tsumiyama⁴, Shunichi Shiozawa⁵, Marie-Christophe Boissier⁶, Natacha Bessis² and Patrice Decker¹, ¹Inserm UMR 1125, Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ²Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ³Institut Pasteur, Paris, Paris, France, ⁴Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Institute for Rheumatic Diseases, Nagahama, Japan, ⁶Rheumatology Department, AP-HP, Avicenne Hospital, Bobigny, France
Background/Purpose: Type I interferons (IFN-I) can be both anti- and pro-inflammatory. Among them, IFN-α inhibits normal Th17 differentiation, whereas it is pathogenic in lupus. The…
Abstract Number: 64 • 2018 ACR/ARHP Annual Meeting
Dietary Magnesium Modulates the Intestinal Microbiome and T Cell Subsets
Teresina Laragione¹, Carolyn Harris¹ and Percio S. Gulko², ¹Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Several studies have demonstrated that Magnesium (Mg) has a key role in the immune responses. Our previous studies showed that a short-term low Mg…
Abstract Number: 146 • 2018 ACR/ARHP Annual Meeting
Mesenchymal Stromal Cell Transferred Mitochondria Elicit an Immune Function Reprogramming That Entails T Regulatory Cell Commitment and Clinical Improvement of Graft Vs Host Disease
Angela C. Court¹, Alice Le-Gatt¹, Patricia Luz-Crawford², Monica Kurte², Maria Ignacia Ortuzar¹, Roberto Elizondo², Rafael A. Contreras², Karina Pino-Lagos², Maroun Khoury^3,4 and Fernando E. Figueroa⁴, ¹Cells for Cells, Santiago, Chile, ²Laboratorio de Inmunología Celular y Molecular, Universidad de los Andes, Santiago, Chile, ³Cells for Cells, Santiago de Chile, Chile, ⁴Program for Translational Research in Cell Therapy, Universidad de los Andes, Santiago de Chile, Chile
Background/Purpose: Mesenchymal stromal cells (MSCs) are progenitor cells with suppressive capacities that have fueled ample translation for the treatment of immune mediated diseases including Graft…
Abstract Number: 781 • 2018 ACR/ARHP Annual Meeting
Simultaneous Identification of Two Biomarkers in ACTIVE LUPUS Nephritis: Autophagy in Treg CELLS and Prolactin Receptors in B Lymphocytes
Luis J. Jara-Quezada¹, Emma Zurita², Ana Durán², Antonio Sanchez³, Reyna Bustamante³, Gabriela Medina⁴, Miguel A Saavedra⁵, María Pilar Cruz-Dominguez³, Olga Vera-Lastra⁶, María Pilar Jiménez-Arellano⁷, Michel Augusto Martínez-Bencomo³ and Azucena Rodriguez², ¹Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional,, Mexico, Mexico, ²Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional,, Mexico City, Mexico, ³Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional "La Raza", Mexico City, Mexico, ⁴Clinical Research Unit, Hospital de Especialidades Centro Medico La Raza,IMSS, Mexico City, Mexico, ⁵Novartis Farmaceutica, Calz de Tlaplan 1779, Mexico, Mexico, ⁶Rheumatology, Instituto Mexicano Seguro Social, Mexico City, Mexico, ⁷Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional "La Raza", Mexico CIty, Mexico
Background/Purpose: Recent studies suggest that autophagy defects contributes to systemic lupus erythematosus (SLE) pathogenesis. Prolactin (PRL) is associated with active SLE and stimulates the immune…
Abstract Number: 1086 • 2018 ACR/ARHP Annual Meeting
Low-Dose IL-2 Combined with Rapamycin Efficiently Promotes Remission of Refractory Systemic Lupus Erythematosus
Zhaoyun Liang¹, Xiaona Jing¹, Meihua Hao¹, Chong Gao², Xiao-Feng Li³ and Junwei Chen¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ³Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease. Regulatory T (Treg) cells and T helper type 17 (Th17) cells play opposite roles…
Abstract Number: 1122 • 2018 ACR/ARHP Annual Meeting
Lymphocyte Immunophenotypes at Randomization on the Scleroderma: Cyclophosphamide or Transplantation Trial: Comparison of Treatment Naïve and DMARD Treated Participants with Healthy Controls
Ankoor Shah¹, Jan Storek², Rob Woolson³, Lynette Keyes-Elstein⁴, Paul Wallace⁵, Maureen D. Mayes⁶, Leslie Crofford⁷, Daniel E. Furst⁸, Ellen Goldmuntz⁹, Richard Nash¹⁰, Peter McSweeney¹⁰ and Keith Sullivan¹¹, ¹Medicine, Duke University Medical Center, Durham, NC, ²University of Calgary, Calgary, AB, Canada, ³Rho Inc, Chapel Hill, NC, ⁴Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC, ⁵Roswell Park Cancer Institute, Buffalo, NY, ⁶Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁷Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁸Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁹NIH, Bethesda, MD, ¹⁰Colorado Blood Cancer Institute, Denver, CO, ¹¹Duke University Medical Center, Durham, NC
Background/Purpose: The Scleroderma:Cyclophosphamide or Transplantation Trial (SCOT) study compared stem cell transplant to monthly cyclophosphamide (CYC) in patients with scleroderma (SSc). We studied baseline lymphocyte…
Abstract Number: 1465 • 2018 ACR/ARHP Annual Meeting
Absolute Number of Regulatory T Cells Decreased While Osteopontin Increased in Peripheral Blood of New Onset Patients with Rheumatoid Arthritis
Jianfang Xie¹, Jiao-Jiao He², Xiao-Feng Li³ and Chong Gao⁴, ¹the second hospital of shanxi medical university, taiyuan, China, ²The Second Hospital of Shanxi Medical Univerity, Taiyuan, China, ³Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA
Background/Purpose: Rheumatoid arthritis (RA) is a progressive immune-mediated disease involving the synovitis that can culminate in joint destruction and early mortality.IL-17-producing T (Th17) cells and…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].